References:
  1. Covid19.who.int. 2021. WHO Coronavirus (COVID-19) . [online] Available at: https://covid19.who.int [Accessed 3 June 2021].
  2. SeyedAlinaghi S, Afsahi AM, MohsseniPour M, et al. Late Complications of COVID-19; a Systematic Review of Current Evidence. Arch Acad Emerg Med. 2021;9(1):e14. Published 2021 Jan 20. doi:10.22037/aaem.v9i1.1058
  3. Ghosh K. COVID-19 pneumonia, immunosuppression, and cytomegalovirus activation: A perspective. Tropical medicine and infectious disease. 2021;67(2):65-6. Editorial commentary.
  4. CASE IPTA. 237 Coinfection With COVID-19 and Cytomegalovirus in Kidney Transplant Recipients–A Case Series.
  5. Iqbal P, Laswi B, Jamshaid MB, Shahzad A, Chaudhry HS, Khan D, et al. The Role of Anticoagulation in Post-COVID-19 Concomitant Stroke, Myocardial Infarction, and Left Ventricular Thrombus: A Case Report. The American journal of case reports. 2021;22:e928852.
  6. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135(5):442-7.
  7. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. Journal of Infection. 2020;81(2):266-75.
  8. Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother. 2013;45(3):260-71.
  9. Carll WC, Rady MY. Cytomegalovirus haemorrhagic enterocolitis associated with severe infection with COVID-19. Clinical case reports. 2021;8(1).
  10. Khatib MY, Shaik KS, Ahmed AA, Alwraidat MA, Mohamed AS. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19. 2021;9(1):148-52.
  11. Merchant EA, Flint K, Barouch DH, Blair BM. Co-infection with coronavirus disease 2019, previously undiagnosed human immunodeficiency virus, Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonitis, with possible immune reconstitution inflammatory syndrome. IDCases. 2021;24:e01153
  12. Amaral PH, Ferreira BM, Roll S, Neves PD, Pivetta LG, Mohrbacher S, et al. COVID-19 and Cytomegalovirus Co-infection: A Challenging Case of a Critically Ill Patient with Gastrointestinal Symptoms. European journal of case reports in internal medicine. 2020;7(10):001911.
  13. Carll WC, Rady MY. Cytomegalovirus haemorrhagic enterocolitis associated with severe infection with COVID-19. Clinical case reports. 2021;8(1).
  14. D’Ardes D, Boccatonda A, Schiavone C, Santilli F, Guagnano MT, Bucci M, et al. A case of coinfection with SARS-COV-2 and cytomegalovirus in the era of COVID-19. European journal of case reports in internal medicine. 2020;7(5).
  15. Geisen WR, Berger J, Schwartz C, Reddy A, Rai B, Wadih G, et al. Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy. IDCases. 2020;22:e00962.
  16. Im JH, Lee J-S, Kwon HY, Chung M-H, Baek J. Epstein–Barr Virus and Cytomegalovirus Reactivation in Patients with COVID-19. 2020.
  17. Khatib MY, Shaik KS, Ahmed AA, Alwraidat MA, Mohamed AS. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19. 2021;9(1):148-52.
  18. Leemans S, Maillart E, Van Noten H, Oliveira Dos Santos L, Leahu LM, Kamgang P, et al. Cytomegalovirus haemorrhagic colitis complicating COVID-19 in an immunocompetent critically ill patient: A case report. Clinical case reports. 2021;9(5):e03600.
  19. Maillet F, Pourbaix A, le Pluart D, Sirmai L, Postolache SA, Couvelard A, et al. Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatments. IDCases. 2021;24:e01111.
  20. Oualim S, Elouarradi A, Hafid S, Naitelhou A, Sabry M. A misleading CMV myocarditis during the COVID-19 pandemic: case report. The Pan African medical journal. 2020;36:167.
  21. 3Shah M, Kakar A, Gogia A, Langer S. Convalescent plasma, cytomegalovirus infection, and persistent leukopenia in COVID-19 recovery phase: What is the link? Journal of postgraduate medicine. 2021;67(2):100-2.
  22. Simonnet A, Engelmann I, Moreau A-S, Garcia B, Six S, El Kalioubie A, et al. High incidence of Epstein–Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infectious diseases now. 2021;51(3):296-9.
  23. Bienvenu A-L, Bleyzac N, Richard J-C, Leboucher G. No time for pending confirmation of invasive fungal disease in critically ill COVID-19 patients—think empirical treatment. Critical Care. 2020;24(1):588.